The Glial Cell Line Derived Neurotrophic Factor pipeline drugs market research report outlays comprehensive information on the Glial Cell Line Derived Neurotrophic Factor targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Glial Cell Line Derived Neurotrophic Factor pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Central Nervous System, and Ophthalmology which include the indications Parkinson’s Disease, Amyotrophic Lateral Sclerosis, Glaucoma, and Keratoconjunctivitis Sicca (Dry Eye). It also reviews key players involved in Glial Cell Line Derived Neurotrophic Factor targeted therapeutics development with respective active and dormant or discontinued products.
The Glial Cell Line Derived Neurotrophic Factor pipeline targets constitutes close to 14 molecules. Out of which, approximately 12 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase II, and Preclinical stages are 4, and 8 respectively. Similarly, the universities portfolio in Phase II, and Discovery comprises 1, and 1 molecule.
Glial Cell Line Derived Neurotrophic Factor overview
Glial -derived neurotrophic factor is a member of the cysteine-knot superfamily of growth factors. It promotes the survival and differentiation of dopaminergic neurons and was able to prevent apoptosis of motor neurons. The mature form of the protein is a ligand for the product of the RET (rearranged during transfection) protooncogene.
For a complete picture of Glial Cell Line Derived Neurotrophic Factor’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
